Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics insider sale by Chief Scientific Officer
Joseph P. Lyssikatos, Enliven Therapeutics' Chief Scientific Officer, reported a sale of 4,000 shares of the company's common stock on 09/26/2025 at a weighted average price of $20.2513 per share. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. After the reported disposition, the reporting person beneficially owns 927,688 shares indirectly through The Lyssikatos Revocable Trust dated 12/15/2011, for which he serves as trustee. The Form 4 was signed by power of attorney on 09/30/2025.
Samuel Kintz, President, CEO and a director of Enliven Therapeutics, Inc. (ELVN), reported a sale of 3,700 shares of the company's common stock on 09/26/2025. The sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024, and executed in multiple trades at prices ranging from $20.00 to $20.27, with a weighted average price of $20.0615. After the reported disposition, the reporting person beneficially owns 915,392 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 is signed by a power of attorney on behalf of the reporting person.
Enliven Therapeutics (ELVN) filing a Form 144 notifies a proposed brokered sale of 4,500 common shares through Jefferies with an aggregate market value of $90,045, planned for 09/29/2025. The shares were acquired as stock options on 08/09/2022 from the company. The filing shows 59,000,000 shares outstanding for the issuer and discloses prior insider sales of 7,500 shares during the past three months with reported gross proceeds totaling roughly $156,197.50. The filer attests there is no undisclosed material adverse information and the transaction will be executed through a broker.
Enliven Therapeutics insider sale reported. Joseph P. Lyssikatos, Chief Scientific Officer and trustee of a revocable trust holding shares, reported a sale of 1,500 shares of Enliven Therapeutics (ELVN) common stock on 09/23/2025 at $20.03 per share. After the reported transaction, the filing shows 931,688 shares beneficially owned indirectly through The Lyssikatos Revocable Trust dated 12/15/2011. The filing notes the sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person on 11/15/2024. The Form 4 was submitted by a power of attorney on 09/25/2025.
Samuel Kintz, President, CEO and Director of Enliven Therapeutics (ELVN), reported a sale of 2,800 shares of common stock on 09/23/2025 at a price of $20.03 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on November 15, 2024. After the transaction, the reporting person beneficially owns 919,092 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee. The Form 4 was signed by Ben Hohl by power of attorney on 09/25/2025.
Enliven Therapeutics Chief Scientific Officer Joseph P. Lyssikatos reported two open-market sales of company common stock executed under a Rule 10b5-1 trading plan. On 09/19/2025 he sold 4,870 shares at a weighted average price of $19.1095 and 2,130 shares at a weighted average price of $20.016, for a total of 7,000 shares sold. The filings state the trades were executed in multiple transactions with sale prices ranging from $18.94 to $20.0469. After these sales the reporting person’s beneficial ownership is reported as 933,188 shares held indirectly through The Lyssikatos Revocable Trust, for which he is trustee. The Form 4 was signed by an attorney-in-fact on 09/23/2025.
Samuel Kintz, President & CEO and director of Enliven Therapeutics (ELVN), reported two open-market sales under a Rule 10b5-1 plan adopted November 15, 2024. On 09/17/2025 he sold 5,000 shares for a weighted-average price of $19.0946, leaving beneficial ownership of 922,892 shares of record held by The Kintz & Egan Trust Dated March 30, 2019 for which he is trustee. On 09/19/2025 he sold 1,000 shares for a weighted-average price of $20.25, reducing beneficial ownership to 921,892 shares. The Form 4 was executed by power of attorney on 09/19/2025 and discloses the plan-based nature of the trades and willingness to provide per-trade price details upon request.
Enliven Therapeutics (ELVN) Form 144 notice shows a proposed sale of 12,500 common shares through Jefferies with an aggregate market value of $249,125, with an approximate sale date of 09/19/2025. The filer states these shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing reports 59,000,000 shares outstanding for the issuer.
The filing also discloses recent insider transactions: 24,500 shares sold by Joseph Lyssikatos during July–August 2025 for total gross proceeds of $526,862.01 across three transactions. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Form 144 notice filed for Enliven Therapeutics (ELVN) by a holder reporting proposed and recent sales of common stock. The filer indicates a proposed sale of 12,500 shares through Jefferies LLC with an aggregate market value of $230,375.00, and reports that the shares were originally acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filing also discloses sales by the same person totaling 25,000 shares during the past three months, producing gross proceeds of $531,767.21. The issuer has 59,000,000 shares outstanding and the proposed sale is scheduled approximately for 09/17/2025. The filer certifies no undisclosed material adverse information and includes standard Rule 144 representations.